Vytrus Biotech (XMAD:VYT) Ending Cash Position: €3.38 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:VYT Vytrus Biotech SA XMAD:VYT
66 GF Score
Price €15.70
GF Value €5.65
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Ending Cash Position?

Vytrus Biotech XMAD:VYT -1.88% 66 Ending Cash Position is €3.38 Mil as of Dec. 2025. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.65 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Vytrus Biotech's Ending Cash Position for the quarter that ended in Dec. 2025 was €3.38 Mil.

Vytrus Biotech's quarterly Ending Cash Position increased from Dec. 2024 (€2.53 Mil) to Jun. 2025 (€3.29 Mil) and increased from Jun. 2025 (€3.29 Mil) to Dec. 2025 (€3.38 Mil).

Vytrus Biotech's annual Ending Cash Position increased from Dec. 2023 (€1.11 Mil) to Dec. 2024 (€2.53 Mil) and increased from Dec. 2024 (€2.53 Mil) to Dec. 2025 (€3.38 Mil).

Vytrus Biotech Ending Cash Position Related Terms

Vytrus Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Ending Cash Position Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 1.28 0.73 1.11 2.53 3.38

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 2.22 2.53 3.29 3.38
XMAD:VYT
66GF Score
Vytrus Biotech SA XMAD:VYT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vytrus Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.528+0.848
=3.38

Vytrus Biotech's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.285+0.091
=3.38

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €3.38 Mil mean?
Vytrus Biotech (XMAD:VYT) has a Ending Cash Position of €3.38 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vytrus Biotech and its competitors.
Is Vytrus Biotech's Ending Cash Position too high?
Vytrus Biotech's current Ending Cash Position is €3.38 Mil. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Ending Cash Position compare to VRTX and REGN?
Vytrus Biotech's Ending Cash Position of €3.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current Ending Cash Position is €3.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.65, compared to a current price of €15.70 — trading 177.9% above its estimated fair value. The current Ending Cash Position is €3.38 Mil. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Ending Cash Position is €3.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €15.70 is trading 177.9% above its estimated GF Value™ of €5.65. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • Ending Cash Position: €3.38 Mil
  • GF Value™: €5.65 vs. price of €15.70 (177.9% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score

Get the complete analysis for XMAD:VYT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.70
Price
€5.65
GF Value